Asher Bio bursts on the scene with $55M Series A
Asher Bio focuses on cis-targeting technology to precisely target discrete immune cell subtypes
funding
DiCE Molecules bags $80M in a Series C
The financing will support the progression of DiCE’s IL-17 antagonist into clinical trials
